| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2420906A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420535A1 Sustained release formulations for growth hormone secretagogues |
| 03/06/2002 | EP1184388A1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 03/06/2002 | EP1184370A2 Compounds with growth hormone releasing properties |
| 03/06/2002 | EP1184035A2 Use of growth hormone secretagogues for treatment of physical performance decline |
| 03/06/2002 | EP1183376A1 Isoflavonoid methylation enzyme |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183074A1 Substituted biaryl ether compounds |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183030A1 Methods of making and using n-desmethylzopiclone |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP1183010A2 Implantable gel compositions and method of manufacture |
| 03/06/2002 | EP0912186B1 Progestogen-anti-progestogen regimens |
| 03/06/2002 | CN1339035A Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1080267C Preparation of intermediat of 19, 11 beta-bridge steroid |
| 03/05/2002 | US6352982 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists |
| 03/05/2002 | US6352974 Oral calcitonin pharmaceutical compositions and methods of making the same |
| 03/05/2002 | CA2056638C 2 .beta., 19-ethylene bridged steroids as aromatase inhibitors |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016426A2 Coaster, a human coactivator of steroid receptors |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016316A1 10-ARYL-11-HBENZO [b]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE |
| 02/28/2002 | WO2002016310A1 Selective androgen receptor modulators and methods of use thereof |
| 02/28/2002 | WO2002015959A2 Compounds and compositions for delivering active agents |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015938A2 Testosterone ester formulation for human use |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015890A1 Transdermal therapeutic system |
| 02/28/2002 | WO2002015889A1 Transdermal therapeutic system for treating restless-legs-syndrome |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015841A2 Medicine for treating female sexual dysfunction by acting on the central nervous system |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001053321A3 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |
| 02/28/2002 | US20020025951 Urogenital disorders |
| 02/28/2002 | US20020025578 Intensified expression of nucleotide sequences in mammal; administer nucleic acids to mammal, transfect nucleotide sequence using voltage, monitor mammal for gene expression |
| 02/28/2002 | US20020023877 Methods for the production of D-chiro-inositol and the use of D-chiro-inositol obtained therefrom |
| 02/28/2002 | DE10040700A1 Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung Salts of biologically active peptides, their preparation and use |
| 02/28/2002 | CA2541871A1 Selective androgen receptor modulators and methods of use thereof |
| 02/28/2002 | CA2420289A1 10-aryl-11-hbenzo [b]fluorene derivatives and analogs for medicinal use |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2419981A1 Coaster, a human coactivator of steroid receptors |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2415349A1 Testosterone ester formulation for human use |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181364A1 Lipid metabolism transcription factor |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181276A1 Morpholino-n-ethyl ester derivative of an indole spla-2 inhibitor |
| 02/27/2002 | EP1181275A1 Thio-oxindole derivatives |
| 02/27/2002 | EP1181009A1 Method of producing submicron particles of a labile agent |
| 02/27/2002 | EP0970105B1 Process for preparing carboxamido-4-azasteroids |
| 02/27/2002 | EP0842193B1 Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | CN1337958A Compounds and methods for modulation of estroglen receptors |
| 02/27/2002 | CN1337956A New Morpholinobenzamide salts |
| 02/27/2002 | CN1337955A Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 02/27/2002 | CN1337953A New thryoid receptor ligands and process II |
| 02/27/2002 | CN1337877A Method of preparing stable suspension of insoluble microparticles |
| 02/21/2002 | WO2002014347A2 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts |
| 02/21/2002 | WO2002014291A1 PPARδ ACTIVATORS |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002014279A1 New aporphine esters and their use in therapy |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013802A2 Method of treating estrogen receptor positive carcinoma |
| 02/21/2002 | WO2002013798A2 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 02/21/2002 | WO2002013782A1 Oral delivery of peptide |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001062270A3 Method for treating hashimoto's thyroiditis |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | US20020022609 Orally active androgens |